Metagenomi (NASDAQ:MGX – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Valuation and Earnings
This table compares Metagenomi and Xeris Biopharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Metagenomi | $52.29 million | 1.07 | -$78.06 million | ($2.40) | -0.62 |
| Xeris Biopharma | $203.07 million | 6.00 | -$54.84 million | ($0.10) | -73.40 |
Analyst Ratings
This is a breakdown of current ratings and price targets for Metagenomi and Xeris Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Metagenomi | 1 | 0 | 3 | 1 | 2.80 |
| Xeris Biopharma | 1 | 2 | 5 | 0 | 2.50 |
Metagenomi currently has a consensus target price of $10.00, indicating a potential upside of 571.14%. Xeris Biopharma has a consensus target price of $10.08, indicating a potential upside of 37.38%. Given Metagenomi’s stronger consensus rating and higher probable upside, equities analysts clearly believe Metagenomi is more favorable than Xeris Biopharma.
Risk & Volatility
Metagenomi has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Profitability
This table compares Metagenomi and Xeris Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Metagenomi | -287.06% | -43.19% | -31.06% |
| Xeris Biopharma | -5.88% | N/A | -4.66% |
Insider & Institutional Ownership
42.8% of Xeris Biopharma shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Xeris Biopharma beats Metagenomi on 10 of the 15 factors compared between the two stocks.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
